Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Fc region is the constant domain at the C-terminal end of an antibody, formed by dimerization of the antibody heavy chains, which allows interaction with immune effector molecules. While Fab regions determine antigen specificity, the Fc region controls immune system activation via binding to Fc receptors (on immune cells such as macrophages, NK cells, and others) and to complement proteins. Engineering the Fc region in therapeutic antibodies modifies immune effector functions (such as ADCC, ADCP, CDC) and pharmacokinetics. The Fc region is not a disease-associated cellular receptor, enzyme, or biomarker but is an integral structural and functional part of therapeutic antibody drugs[1][2][5][6][7].
Effector cell recruitment via Fc receptor binding (ADCC, ADCP) Complement activation (CDC) Extended half-life via neonatal Fc receptor (FcRn) binding
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fragment crystallizable region of immunoglobulin (Fc region) (Fc region).